Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases
31 Agosto 2023 - 4:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced a drug discovery
agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan;
President and CEO: Gyo Sagara; “Ono”) to discover and develop novel
antibodies for the treatment of autoimmune diseases.
“Ono has a strong and proven track record in developing antibody
candidates in areas of need, including the development of the
anti-PD-1 antibody Opdivo, which has had a tremendous impact for
patients and researchers,” said Emily M. Leproust, Ph.D., CEO and
co-founder of Twist Bioscience. “This collaboration bringing
together our antibody discovery expertise with Ono’s experience in
drug development has the potential to lead to future breakthrough
treatment options for patients with autoimmune diseases.”
Under the terms of the agreement, Twist will utilize the Twist
Biopharma Solutions Library of Libraries to conduct research
activities to discover novel antibodies against targets identified
by Ono. Twist’s Library of Libraries is an expansive collection of
synthesized antibody libraries based on naturally occurring
sequences that harness innovative structural and developability
features to cover a wide range of drug targets. Twist will receive
research fees, success-based clinical and regulatory milestones, as
well as royalties on product sales. As part of the strategic
collaboration, Ono will also utilize the scientific expertise of
the Biopharma Solutions team and Twist’s Premium Project Management
services to evaluate new targets and generate comprehensive
discovery campaigns. Ono will be responsible for the development,
manufacturing and commercialization of any products resulting from
the collaboration.
“We are actively working to create biologics like antibodies in
order to address unmet medical needs for a wide range of diseases
including autoimmune diseases. We are very pleased to collaborate
with Twist at this time in the area of autoimmune diseases and are
confident that their expertise in antibody discovery and their
impressive collection of diverse and highly specific antibody
libraries will bring us potential functional antibodies,” said Dr.
Toichi Takino, Senior Executive Officer / Executive Director,
Discovery and Research of Ono. “We believe that this new
collaboration will enhance our biologics drug discovery efforts and
bring innovative drugs for patients as soon as possible.”
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an
R&D-oriented pharmaceutical company committed to creating
innovative medicines in specific areas. Ono focuses its research on
oncology, immunology, neurology and specialty research with high
medical needs as priority areas for discovery and development of
innovative medicines. For further information, please visit the
company’s website at https://www.ono-pharma.com/en.
About Twist Biopharma Solutions (The Biologics Discovery and
Optimization Division of Twist Bioscience)
Twist Biopharma Solutions combines high-throughput DNA synthesis
technology, deep expertise in antibody engineering and in vivo, in
vitro and in silico discovery methods to provide end-to-end
antibody discovery solutions across the preclinical continuum and
tailored to our partner’s specific needs. By leveraging our unique
ability to manufacture DNA at scale, we can construct proprietary
antibody libraries with discovery beginning with either in vivo or
in vitro diversity. Our Library of Libraries gives our partners an
integral and unbiased resource for antibody therapeutic discovery
and optimization. This precise and rational approach to library
fabrication combined with sophisticated bioinformatics and software
expertise expedites antibody discovery by decreasing risk,
increasing speed, and lowering the failure rate for antibody
therapeutic development. Additionally, in vivo discovery approaches
including single B cell screening and hybridoma discovery enable
parallel paths where multiple technology methods can be leveraged
to create a panel of highly diverse antibody leads. Our automated
screening and panning processes enable us to identify high affinity
leads that our partners can move forward into the clinic. We also
offer supporting development capabilities, including IgG
conversion, expression, purification, biophysical characterization,
and functional characterization.
For more information visit:
https://www.twistbioscience.com/products/antibody-discovery/twist-bioscience-and-abveris
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including, but not limited to, statements regarding the
potential success of the collaboration and the achievement of any
clinical or regulatory milestones or product sales, are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
workforce reduction, transition of production to the Factory of the
Future and reduced investments in DNA data storage; the ability to
attract new customers and retain and grow sales from existing
customers; the ability of Twist to achieve sufficient revenue to
achieve or maintain positive cash flow from operations or
profitability in any given period; risks and uncertainties of
rapidly changing technologies and extensive competition in
synthetic biology that could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties of the
retention of significant customers; the ability of Twist Bioscience
to successfully integrate acquired companies and to achieve
expected benefits from acquisitions; supply chain and other
disruptions caused by the COVID-19 pandemic or otherwise; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on August 7,
2023 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230831082228/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs 925-202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024